Magnetic transferrin nanoparticles (MTNs) assay as a novel isolation approach for exosomal biomarkers in neurological diseases

Biomaterials Research

Research Article

JeongYeon Hong¹  Kyunggon Kim¹  Thuy Nguyen Thi Dao²  Myoung Gyu Kim²  Yong Shin²  Huifang Liu²  Yoon Ok Jang²  Bonhan Koo²  Hee-Sung Ahn³  Wangyong Shin⁴  Jae-Hong Lee⁴  Eun-Jae Lee⁴  Young-Min Lim⁴  Sun Ju Chung⁴ 

[1] Asan Institute for Life Sciences, Asan Medical Center, 05505, Seoul, Republic of Korea;Department of Biomedical Sciences, University of Ulsan College of Medicine, 05505, Seoul, Republic of Korea;Department of Biotechnology, College of Life Science and Biotechnology, Yonsei University, 03722, Seoul, Republic of Korea;Department of Convergence Medicine, Asan Medical Center, 05505, Seoul, Republic of Korea;Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, 05505, Seoul, Republic of Korea;

关键词: Brain-derived blood exosome;    Neurological disease;    Extracellular vesicle;    Magnetic nanoparticle;    Liquid chromatography − mass spectrometry;   

DOI  :  10.1186/s40824-023-00353-2

 received in 2022-11-17, accepted in 2023-02-05,  发布年份 2023

来源: Springer

【 摘 要 】

BackgroundBrain-derived exosomes released into the blood are considered a liquid biopsy to investigate the pathophysiological state, reflecting the aberrant heterogeneous pathways of pathological progression of the brain in neurological diseases. Brain-derived blood exosomes provide promising prospects for the diagnosis of neurological diseases, with exciting possibilities for the early and sensitive diagnosis of such diseases. However, the capability of traditional exosome isolation assays to specifically isolate blood exosomes and to characterize the brain-derived blood exosomal proteins by high-throughput proteomics for clinical specimens from patients with neurological diseases cannot be assured. We report a magnetic transferrin nanoparticles (MTNs) assay, which combined transferrin and magnetic nanoparticles to isolate brain-derived blood exosomes from clinical samples.MethodsThe principle of the MTNs assay is a ligand-receptor interaction through transferrin on MTNs and transferrin receptor on exosomes, and electrostatic interaction via positively charged MTNs and negatively charged exosomes to isolate brain-derived blood exosomes. In addition, the MTNs assay is simple and rapid (< 35 min) and does not require any large instrument. We confirmed that the MTNs assay accurately and efficiently isolated exosomes from serum samples of humans with neurodegenerative diseases, such as dementia, Parkinson's disease (PD), and multiple sclerosis (MS). Moreover, we isolated exosomes from serum samples of 30 patients with three distinct neurodegenerative diseases and performed unbiased proteomic analysis to explore the pilot value of brain-derived blood protein profiles as biomarkers.ResultsUsing comparative statistical analysis, we found 21 candidate protein biomarkers that were significantly different among three groups of neurodegenerative diseases.ConclusionThe MTNs assay is a convenient approach for the specific and affordable isolation of extracellular vesicles from body fluids for minimally-invasive diagnosis of neurological diseases.

【 授权许可】

CC BY   
© The Author(s) 2023

【 图 表 】

Fig. 4

Fig. 9

40645_2023_538_Article_IEq106.gif

Fig. 5

Fig. 2

Fig. 4

40249_2023_1061_Article_IEq22.gif

Fig. 3

Fig. 1